Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study

• Published in: Cancers Vol. 16; no. 7; p. 1442
• Main Authors: Kouvela, Marousa, Livanou, Maria Effrosyni, Stefanou, Dimitra T, Vathiotis, Ioannis A, Sarropoulou, Fotini, Grammoustianou, Maria, Dimakakos, Evangelos, Syrigos, Nikolaos
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2024
• Subjects: Adenocarcinoma; Anticoagulants; Blood; Blood clot; Blood platelets; Cancer; Cancer patients; Cancer therapies; Cardiovascular disease; Care and treatment; Chemotherapy; Clinical medicine; Cohort analysis; Disease prevention; Drug dosages; Drug therapy; Embolism; Health aspects; Hemoglobin; Heparin; Histology; Immunotherapy; Lung cancer; Molecular weight; Morbidity; Mortality; Oncology; Oncology, Experimental; Patient compliance; Patients; Pulmonary embolism; Respiratory agents; Risk factors; Thromboembolism; Thrombosis; Tumors; lung cancer; venous thromboembolic disease; tinzaparin; thromboprophylaxis
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16071442

The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk. This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested. In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not ( = 0.26 and = 0.32, respectively). Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE.